1
|
Muñoz NG, Ortega S, Solanich X, Cid J, Díaz M, Moreno AB, Ancochea Á, Santos M, Hernández I, Sanchez JM, Luaña A, García J, Escoda L, Medina L, Ferrer GJ, López J, Céspedes R, Díaz JA, Pons V, Valcárcel D, Grifols JR. Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group. Blood Transfus 2024; 22:176-184. [PMID: 37677097 PMCID: PMC10920070 DOI: 10.2450/bloodtransfus.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Accepted: 07/06/2023] [Indexed: 09/09/2023]
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a low prevalence disease characterized by severe deficiency of the enzyme ADAMTS13, leading to the development of thrombotic microangiopathy (TMA) and often resulting in severe organ disfunction. TTP is an extremely serious condition and, therefore, timely and appropriate treatment is critical to prevent life-threatening complications.Over the past 25 years, significant advances in the understanding of the pathophysiology of immune TTP have led to the development of readily available techniques for measuring ADAMTS13 levels, as well as new drugs that are particularly effective in the acute phase and in preventing relapses. These developments have improved the course of the disease.Given the complexity of the disease and its various clinical and laboratory manifestations, early diagnosis and treatment can be challenging.To address this challenge, a group of experienced professionals from the Catalan TTP group have developed this consensus statement to standardize terminology, diagnosis, treatment and follow up for immune TTP, based on currently available scientific evidence in the field. This guidance document aims to provide healthcare professionals with a comprehensive tool to make more accurate and timely diagnosis of TTP and improve patient outcomes.
Collapse
Affiliation(s)
- Nadia García Muñoz
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary of Bellvitge, L’Hospitalet de Llobregat, Catalonia, Spain
| | - Sandra Ortega
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary of Bellvitge, L’Hospitalet de Llobregat, Catalonia, Spain
| | - Xavier Solanich
- Internal Medicine, Hospital Universitary of Bellvitge, L’Hospitalet de Llobregat, Catalonia, Spain
| | - Joan Cid
- Hemotherapy and Hemostasis, ICMHO, Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
| | - Maribel Díaz
- Hemostasis and Erythropathology Pathology Department CDB, Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
| | - Ana B. Moreno
- Hemostasis and Erythropathology Pathology Department CDB, Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
| | - Águeda Ancochea
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary Germans Trias I Pujol, Badalona, Catalonia, Spain
| | - Mireia Santos
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary Germans Trias I Pujol, Badalona, Catalonia, Spain
| | - Inés Hernández
- Hemathology, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Juan M. Sanchez
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary Arnau de Vilanova, Lleida, Catalonia, Spain
| | - Armando Luaña
- Hemathology, Hospital Universitary Arnau de Vilanova, Lleida, Catalonia, Spain
| | - Jose García
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary de Tarragona Joan XIII, University Rovira i Virgili, Catalonia, Spain
| | - Lourdes Escoda
- Hemathology, Catalan Institute of Oncology Tarragona Hospital Universitary de Tarragona Joan XIII, University Rovira i Virgili, Tarragona, Catalonia, Spain
| | - Laura Medina
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
| | - Gonzalo J. Ferrer
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
| | - Jordi López
- Hemathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
| | - Roberto Céspedes
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Doctor Josep Trueta, Girona, Catalonia, Spain
| | - Johana A. Díaz
- Hemathology, Catalan Institute of Oncology, Hospital Doctor Josep Trueta, Girona, Catalonia, Spain
| | - Verónica Pons
- Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary de la Vall d’Hebron, Barcelona, Catalonia, Spain
| | - David Valcárcel
- Hemathology, VHIO, Hospital Universitary de la Vall d’Hebron, Barcelona, Catalonia, Spain
| | - Joan R. Grifols
- Medical Direction, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Barcelona, Catalonia, Spain
| |
Collapse
|
2
|
Salvia R, Rico LG, Bradford JA, Ward MD, Olszowy MW, Martínez C, Madrid-Aris ÁD, Grífols JR, Ancochea Á, Gomez-Muñoz L, Vives-Pi M, Martínez-Cáceres E, Fernández MA, Sorigue M, Petriz J. Fast-screening flow cytometry method for detecting nanoplastics in human peripheral blood. MethodsX 2023; 10:102057. [PMID: 36851978 PMCID: PMC9958479 DOI: 10.1016/j.mex.2023.102057] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 02/02/2023] [Indexed: 02/08/2023] Open
Abstract
Plastic pollution is a global problem. Animals and humans can ingest and inhale plastic particles, with uncertain health consequences. Nanoplastics (NPs) are particles ranging from 1 nm to 1000 nm that result from the erosion or breakage of larger plastic debris, and can be highly polydisperse in physical properties and heterogeneous in composition. Potential effects of NPs exposure may be associated with alterations in the xenobiotic metabolism, nutrients absorption, energy metabolism, cytotoxicity, and behavior. In humans, no data on NPs absorptions has been reported previously. Given that their detection relies significantly on environmental exposure, we have prospectively studied the presence of NPs in human peripheral blood (PB). Specifically, we have used fluorescence techniques and nanocytometry, together with the staining of the lipophilic dye Nile Red (NR), to demonstrate that NPs can be accurately detected using flow cytometry.•Potential effects of nanoplastics exposure.•Fluorescence techniques and nanocytometry.•Accurate detection using flow cytometry.
Collapse
Affiliation(s)
- Roser Salvia
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Laura G Rico
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain
| | | | | | - Michael W Olszowy
- Sartorius Stedim North America, inc., Arvada, Colorado, United States
| | - Cristina Martínez
- Lleida Biomedical Research Institute's Dr. Pifarré Foundation (IRBLleida), Lleida, Spain
| | | | | | | | - Laia Gomez-Muñoz
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Marta Vives-Pi
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Eva Martínez-Cáceres
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Marco A Fernández
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain
| | - Marc Sorigue
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain
| | - Jordi Petriz
- Germans Trias i Pujol Research Institute (IGTP), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Barcelona, Spain
| |
Collapse
|
3
|
Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern ofJAK2V617F allele burden in polycythemia vera. Eur J Haematol 2014; 94:251-7. [DOI: 10.1111/ejh.12425] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/27/2014] [Indexed: 12/26/2022]
Affiliation(s)
- Anna Angona
- Hematology Department; Hospital del Mar; Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
| | - Alberto Alvarez-Larrán
- Hematology Department; Hospital del Mar; Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
| | - Beatriz Bellosillo
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
- Pathology Department; Hospital del Mar; Barcelona Spain
- Universitat Pompeu Fabra; Barcelona Spain
| | - Luz Martínez-Avilés
- Universitat Autònoma de Barcelona; Barcelona Spain
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
- Pathology Department; Hospital del Mar; Barcelona Spain
| | - Laura Camacho
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
- Pathology Department; Hospital del Mar; Barcelona Spain
| | - Concepción Fernández-Rodríguez
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
- Pathology Department; Hospital del Mar; Barcelona Spain
| | - Silvia Pairet
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
- Pathology Department; Hospital del Mar; Barcelona Spain
| | - Raquel Longarón
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
- Pathology Department; Hospital del Mar; Barcelona Spain
| | - Águeda Ancochea
- Hematology Department; Hospital del Mar; Barcelona Spain
- Universitat Autònoma de Barcelona; Barcelona Spain
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
| | - Alicia Senín
- Hematology Department; Hospital del Mar; Barcelona Spain
| | | | - Carles Besses
- Hematology Department; Hospital del Mar; Barcelona Spain
- Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM; Barcelona Spain
| |
Collapse
|
4
|
Ancochea Á, Salar A, García-Pallarols F, Gimeno E, Fernández-Rodriguez C, Sánchez-González B. [Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years]. Med Clin (Barc) 2014; 144:544-7. [PMID: 25110180 DOI: 10.1016/j.medcli.2014.04.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 04/09/2014] [Accepted: 04/10/2014] [Indexed: 10/24/2022]
Abstract
BACKGROUND AND OBJECTIVE The optimal treatment of aggressive non-Hodgkin lymphoma (NHL) in elderly patients remains controversial. We aimed to evaluate the impact of age and use of anthracyclines. PATIENTS AND METHOD Retrospective analysis of patients with aggressive NHL aged over 70 years old. RESULTS One hundred and twenty-eight patients with a median age of 76 years (70-91). Eighty-eight percent received chemotherapy, and 72% received anthracyclines. The overall response rate was 70%, 51% with a complete response (CR)/uncertain complete response and 19% with a partial response (PR). Overall survival (OS) was 28 months (95% confidence interval 18-78). In the diffuse large B-cell lymphoma group, progression-free survival (PFS) and OS were significantly better in patients who achieved CR versus PR. The use of anthracyclines was associated with CR, the international prognostic index (IPI) was associated with both survival and response, and age showed no association. CONCLUSIONS In patients aged ≥ 70 years with aggressive lymphoma who received chemotherapy, the IPI but not age and the use of anthracyclines showed a prognostic impact. Therefore, in elderly patients with aggressive lymphomas, the use of anthracyclines should be considered and therapeutic decisions should not be based on age exclusively.
Collapse
Affiliation(s)
- Águeda Ancochea
- Departamento de Hematología, Grup de Recerca de Neoplàsies Hematològiques, Hospital del Mar-IMIM, Barcelona, España
| | - Antonio Salar
- Departamento de Hematología, Grup de Recerca de Neoplàsies Hematològiques, Hospital del Mar-IMIM, Barcelona, España
| | - Francesc García-Pallarols
- Departamento de Hematología, Grup de Recerca de Neoplàsies Hematològiques, Hospital del Mar-IMIM, Barcelona, España
| | - Eva Gimeno
- Departamento de Hematología, Grup de Recerca de Neoplàsies Hematològiques, Hospital del Mar-IMIM, Barcelona, España
| | | | - Blanca Sánchez-González
- Departamento de Hematología, Grup de Recerca de Neoplàsies Hematològiques, Hospital del Mar-IMIM, Barcelona, España.
| |
Collapse
|
5
|
Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Carlos Hernández-Boluda J, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea Á, Senín A, Longarón R, Navarro B, Collado M, Besses C. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 2014; 89:517-23. [PMID: 24458835 DOI: 10.1002/ajh.23676] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Revised: 01/20/2014] [Accepted: 01/20/2014] [Indexed: 01/30/2023]
Abstract
The JAK2V617F allele burden has been identified as a risk factor for vascular events and myelofibrotic transformation in polycythemia vera (PV) and essential thrombocythemia (ET). However, all previous studies have evaluated a single time point JAK2V617F measurement. Therefore, the frequency and the clinical significance of changes in the JAK2V617F mutant load occurring during the disease evolution remain unknown. In the present study, JAK2V617F monitoring was performed during the follow-up of 347 patients (PV = 163, ET = 184). According to their JAK2V617F evolutionary patterns, patients were stratified as stable < 50% (n = 261), stable ≥50% (n = 52), progressive increase (n = 24) and unexplained decrease (n = 10). After a 2,453 person-years follow-up, a total of 59 thrombotic events, 16 major hemorrhages, and 27 cases of myelofibrotic transformations were registered. At multivariate analyses, patients with a persistently high (≥50%) or unsteady JAK2V617F load during follow-up had an increased risk of myelofibrotic transformation (Incidence rate ratio [IRR]: 20.7, 95% CI: 6.5-65.4; P < 0.001) and a trend for a higher incidence of thrombosis (IRR: 1.7, 1-3.3; P = 0.05) than patients with a stable allele burden below 50%. In conclusion, JAK2V617F monitoring could be useful in patients with PV and ET for predicting disease's complications, especially myelofibrotic transformation.
Collapse
Affiliation(s)
| | - Beatriz Bellosillo
- Pathology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| | - Arturo Pereira
- Hemotherapy and Hemostasis Department; Hospital Clínic, Universitat de Barcelona; Barcelona
| | | | | | - Luz Martínez-Avilés
- Pathology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| | | | - Montse Gómez
- Hematology and Medical Oncology Department; Hospital Clínico Universitario; Valencia
| | - Luis Lombardía
- Molecular Laboratory; Centro Nacional de Investigaciones Oncológicas; Madrid
| | - Anna Angona
- Hematology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| | - Águeda Ancochea
- Hematology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| | - Alicia Senín
- Hematology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| | - Raquel Longarón
- Pathology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| | - Blanca Navarro
- Hematology and Medical Oncology Department; Hospital Clínico Universitario; Valencia
| | - María Collado
- Hematology and Medical Oncology Department; Hospital Clínico Universitario; Valencia
| | - Carlos Besses
- Hematology Department; Hospital del Mar, Universitat Autònoma de Barcelona; Barcelona
| |
Collapse
|